article thumbnail

Investigating antipsychotics in a Parkinson’s disease psychosis model

Drug Target Review

Clozapine induced a significantly different brain state and pimavanserin, the only licensed compound for PD-P, turned out to be more similar to Mesdopetam on the global scale. During the years 2007-2010 he served as board member of SwedenBIO, the Swedish Biotech industry association. In 2013, Nicholas co-founded IRLAB Sweden.

Disease 105
article thumbnail

FDA More Selective About Convening Advisory Committee Panels During Pandemic | 2021-01-18

The Pharma Data

FDA advisory committees recommended just 50 percent of the 18 new therapies and indications they reviewed in 2020, the lowest rate since 2007, and the agency seems to be reserving the panels for more problematic applications, according to Prevision Policy, a Washington, D.C.-based based research firm.

FDA 52
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

International Women’s Day: Female life science leaders

Drug Discovery World

Linda Powers, CEO, Northwest Biotherapeutics Powers has served as the Chairman of NW Bio since 2007, and as CEO since 2011. She has over 15 years’ experience in corporate finance and restructurings, mergers and acquisitions, joint ventures and intellectual property licensing.

article thumbnail

Janssen Announces Novel Mechanism of Action that Shows Promise Against Dengue in Data Published in Nature

The Pharma Data

The Janssen dengue compound discovery program started in 2007. licensed the compound series in 2015, and is continuing to advance the compound into clinical development. This effort built upon four years of work on the novel antiviral inhibitor by KU Leuven Rega Institute, CD3, and the Wellcome Trust. Janssen Pharmaceutica, N.V.

Virus 52
article thumbnail

Where is the drug discovery expertise happening in the UK?

Drug Discovery World

Dr Tralau-Stewart says: “Indeed, many academic institutions have established new ways of supporting the discovery pipeline, providing tech transfer offices to support licensing, and entrepreneurship and start-up support through fundraising, accelerators, and incubators.

Drugs 189
article thumbnail

EISAI PUBLISHES SOCIETAL VALUE OF LECANEMAB USING PHASE 3 CLARITY AD DATA IN PEER-REVIEWED NEUROLOGY AND THERAPY JOURNAL

The Pharma Data

Eisai submitted a supplemental Biologics License Application (sBLA) to the FDA for approval under the traditional pathway on January 6, 2023. Eisai obtained the global rights to study, develop, manufacture and market lecanemab for the treatment of AD pursuant to an agreement with BioArctic in December 2007. In the U.S.,

article thumbnail

Alzprotect Strengthens Its Intellectual Property Portfolio for Its First-in-Class Clinical Stage Drug Ezeprogind

The Pharma Data

Alzprotect co-owns or has an exclusive worldwide license from the French National Institute of Health and Medical research (Inserm) and the University of Lille (France) on a total of 58 patents related to Ezeprogind in 39 countries. Alzprotect is financed by the XERYS fund (Paris). About Alzprotect.

Drugs 40